替雷利珠单抗（抗TIGIT）用于小细胞肺癌：Skyscraper-02，一场熊熊大火。
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
作者信息
Brazel Danielle, Ou Sai-Hong Ignatius, Nagasaka Misako
机构信息
Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
Chao Family Comprehensive Cancer Center, Orange, CA, USA.
出版信息
Lung Cancer (Auckl). 2023 Jan 5;14:1-9. doi: 10.2147/LCTT.S379389. eCollection 2023.
Abstract
Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.
摘要
小细胞肺癌（SCLC）的特点是进展迅速且预后较差。尽管II期CITYSCAPE-02试验发现，在阿替利珠单抗和化疗中加入替雷戈珠单抗时，非小细胞肺癌（NSCLC）患者的客观缓解率（ORR）和无进展生存期（PFS）有所改善，但III期SKYSCRAPER-02试验未能发现替雷戈珠单抗对SCLC患者的PFS或总生存期（OS）有获益。根据III期IMpower133研究，阿替利珠单抗是首个在广泛期SCLC中显示出生存获益的免疫疗法。鉴于免疫疗法已成为SCLC患者的标准治疗方案，需要进一步研究增强免疫系统的方法，以更好地治疗这些患者。
相似文献
1
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.替雷利珠单抗（抗TIGIT）用于小细胞肺癌：Skyscraper-02，一场熊熊大火。
Lung Cancer (Auckl). 2023 Jan 5;14:1-9. doi: 10.2147/LCTT.S379389. eCollection 2023.
2
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.替雷利珠单抗联合阿替利珠单抗对比安慰剂联合阿替利珠单抗作为 PD-L1 选择的非小细胞肺癌一线治疗（CITYSCAPE）：一项随机、双盲、II 期研究的主要和随访分析。
Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.
3
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.SKYSCRAPER-02：替雷戈珠单抗联合阿替利珠单抗加化疗用于未经治疗的广泛期小细胞肺癌
J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.
4
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study.重新思考小细胞肺癌的治疗策略：从 SKYSCRAPER-02 研究中的替雷利珠单抗中获得的经验教训。
Med. 2024 Apr 12;5(4):281-284. doi: 10.1016/j.medj.2024.02.001.
5
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.简要报告：阿特珠单抗联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌患者维持治疗的探索性分析。
J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016. Epub 2022 Jun 25.
6
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.依托泊苷-铂类-阿替利珠单抗治疗广泛期小细胞肺癌中不良预测因素的研究。
Thorac Cancer. 2022 Dec;13(23):3384-3392. doi: 10.1111/1759-7714.14697. Epub 2022 Oct 23.
7
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).阿替利珠单抗联合卡铂和依托泊苷治疗广泛期小细胞肺癌患者的总生存更新和 PD-L1 亚组分析（IMpower133）。
J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13.
8
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.一线免疫疗法联合化疗治疗广泛期小细胞肺癌患者的疗效和安全性：一项系统评价和网状Meta分析
J Oncol. 2020 Sep 29;2020:2368164. doi: 10.1155/2020/2368164. eCollection 2020.
9
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).在阿特珠单抗治疗广泛期小细胞肺癌的 III 期研究（IMpower133）中，日本患者的亚组分析。
Clin Lung Cancer. 2019 Nov;20(6):469-476.e1. doi: 10.1016/j.cllc.2019.07.005. Epub 2019 Jul 31.
10
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.免疫治疗时代广泛期小细胞肺癌的系统治疗。
Curr Treat Options Oncol. 2020 Jun 29;21(8):64. doi: 10.1007/s11864-020-00762-8.
引用本文的文献
1
Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors.神经递质：肿瘤免疫检查点抑制剂治疗耐药性的一个新出现的靶点。
Mol Cancer. 2025 Aug 11;24(1):216. doi: 10.1186/s12943-025-02413-8.
2
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.替雷利珠单抗与TIGIT：开创癌症免疫治疗的新时代。
Front Pharmacol. 2025 Jun 11;16:1568664. doi: 10.3389/fphar.2025.1568664. eCollection 2025.
3
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy.通过联合阿扎胞苷疗法释放TIGIT在增强急性髓系白血病治疗策略方面的潜力。
NPJ Precis Oncol. 2025 May 15;9(1):142. doi: 10.1038/s41698-025-00933-6.
4
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.整合应激反应途径协调肺癌中多个免疫检查点的翻译控制。
Cancer Res. 2025 Jul 15;85(14):2574-2590. doi: 10.1158/0008-5472.CAN-24-3844.
5
Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy.有前景的新型抗TIGIT药物：癌症免疫治疗中的隐秘盟友
Clin Transl Sci. 2025 Apr;18(4):e70212. doi: 10.1111/cts.70212.
6
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma.程序性死亡受体1（PD-1）和T细胞免疫球蛋白和ITIM结构域（TIGIT）免疫检查点抑制剂联合使用可在间皮瘤中引发强烈的抗肿瘤反应。
J Exp Clin Cancer Res. 2025 Feb 12;44(1):51. doi: 10.1186/s13046-025-03314-w.
7
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.利用肿瘤微环境：通过调节上皮-间质转化实现靶向癌症治疗
J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6.
8
Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer.肺癌中综合应激反应途径对多个免疫检查点的协同翻译控制。
bioRxiv. 2024 Oct 28:2024.10.23.619897. doi: 10.1101/2024.10.23.619897.
9
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.新型免疫检查点抑制剂联合治疗与化疗作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项网络荟萃分析。
Thorac Cancer. 2024 May;15(15):1246-1262. doi: 10.1111/1759-7714.15310. Epub 2024 Apr 16.
10
Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness.硫磺素通过减轻自然杀伤细胞诱导的干性来抑制结直肠癌。
Pharmaceuticals (Basel). 2024 Mar 18;17(3):387. doi: 10.3390/ph17030387.
本文引用的文献
1
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.替雷利珠单抗联合阿替利珠单抗对比安慰剂联合阿替利珠单抗作为 PD-L1 选择的非小细胞肺癌一线治疗（CITYSCAPE）：一项随机、双盲、II 期研究的主要和随访分析。
Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.
2
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.转录因子程序和免疫途径激活模式定义了具有不同治疗弱点的 SCLC 的四个主要亚型。
Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21.
3
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合或不联合 Tremelimumab 与单用依托泊苷联合顺铂一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、3 期临床试验的更新结果。
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
4
Tiragolumab Impresses in Multiple Trials.替雷戈洛单抗在多项试验中表现出色。
Cancer Discov. 2020 Aug;10(8):1086-1087. doi: 10.1158/2159-8290.CD-NB2020-063. Epub 2020 Jun 23.
5
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗：随机、双盲、III 期 KEYNOTE-604 研究。
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
6
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.优化的分段放疗联合抗 PD-L1 和抗 TIGIT：一种有前途的新组合。
J Immunother Cancer. 2019 Jun 25;7(1):160. doi: 10.1186/s40425-019-0634-9.
7
CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.CD155 在人乳腺癌中的表达：临床意义及与自然杀伤细胞浸润的相关性。
Life Sci. 2019 Aug 15;231:116543. doi: 10.1016/j.lfs.2019.116543. Epub 2019 Jun 6.
8
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.关于人小细胞肺癌中PD-L1和CD155表达的生存分析以及与相关受体的比较
Oncol Lett. 2019 Mar;17(3):2960-2968. doi: 10.3892/ol.2019.9910. Epub 2019 Jan 9.
9
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function.PVRIG 和 PVRL2 在肿瘤中诱导表达，并抑制 CD8 T 细胞功能。
Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.
10
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
Zotero 插件